Early changes in tubular dysfunction markers and phosphorus metabolism regulators as a result of switching from entecavir to tenofovir alafenamide fumarate nucleoside analog therapy for chronic hepatitis B patients

Hepatol Res. 2020 Mar;50(3):402-404. doi: 10.1111/hepr.13451.
No abstract available

Keywords: chronic hepatitis B; entecavir; fibroblast growth factor 23; phosphorus metabolism; renal tubular dysfunction; tenofovir alafenamide; urinary liver-type fatty acid-binding protein.

Publication types

  • Letter